Sarepta Therapeutics Stock Tumbles After Trial Data

Core Insights - Sarepta Pharmaceuticals Inc's stock has dropped significantly by 31.4% to $16.77, despite reporting strong revenue, due to a wider-than-expected loss per share and disappointing trial results for gene-therapy treatments for Duchenne muscular dystrophy [1][2] Company Performance - The stock has experienced volatility, previously reaching a nine-year low of $10.41 on July 24, but has now lost most of its gains, with an overall decline of 85.7% since the beginning of 2025 [2] Options Market Activity - Options trading has been active, with 19,000 calls and 5,973 puts traded today, indicating a shift in trader sentiment as they buy on the dip [3][4] - The most popular options contracts are the November 25 call and the December 17.50 call, with new positions opening in the latter [3] - The 10-day put/call volume ratio stands at 1.30, indicating a higher-than-usual interest in puts, ranking above 89% of readings from the past year [4]